Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-CTR-FAPI
- Development stage
- Phase 1
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-CTR-FAPI is a radiopharmaceutical used for positron emission tomography/computed tomography (PET/CT) imaging in oncology. It is a gallium 68-labeled fibroblast activation protein inhibitor (FAPI) that targets the fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts within the tumor stroma. The CTR modification refers to a covalent targeted radioligand design, aiming to improve detection sensitivity and diagnostic accuracy over standard FAPIs. In clinical studies, [68Ga]Ga-CTR-FAPI PET/CT has demonstrated superior detection rates and diagnostic accuracy compared with [18F]FDG PET/CT, particularly in medullary thyroid carcinoma and other malignancies. Its mechanism of action involves binding to FAP on activated fibroblasts, enabling precise visualization of primary tumors and metastases for improved disease management[6][9].
- Other names
- 68Ga-CTR-FAPI[68Ga]Ga-CTR-FAPI
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-CTR-FAPI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-CTR-FAPI.